Patent ID: 8772290

Claim:
A method for treating pancreatic cancer, psoriasis, diabetic retinopathy, or macular degeneration in a subject in need thereof, comprising administering to the subject an alpha-arylmethoxyacrylate of the following formula 1, or a pharmaceutically acceptable salt, a hydrate, or a solvate thereof: wherein R 1 and R 5 are each independently H, hydroxy, halogen, C 1-6 alkyl, or C 1-6 alkoxy; R 2 , R 3 and R 4 are each independently H, hydroxy, halogen, formyl, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 heteroaryl, or any one of formulae A to C: wherein n is an integer of 0 to 4; R 11 is H, hydroxy, cyano, C 1-4 alkyl, C 2-6 alkenyl, C 1-6 alkoxy, C 1-4 alkoxyC 1-4 alkyl, C 3-8 cycloalkylC 1-4 alkyl, or C 2-7 heterocycloalkylC 1-4 alkyl, C 1-4 alkylamino, or diC 1-4 alkylamino; R 12 and R 13 are each independently H, halogen, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkylC 1-4 alkyl, C 2-7 heterocycloalkylC 1-4 alkyl, C 6-12 aryl, C 6-12 arylC 1-4 alkyl, C 6-12 aryloxyC 1-4 alkyl, or C 3-6 heteroarylC 1-4 alkyl, or combine together to form C 2-7 heterocycloalkyl; and R 14 is H, hydroxy, C 3-8 cycloalkyl, C 2-7 heterocycloalkyl, C 6-12 aryl, C 6-12 arylC 1-4 alkyl, C 6-12 aryloxy, C 3-6 heteroaryl, C 1-4 alkylamino, diC 1-4 alkylamino, or said alkyl, alkenyl and alkoxy each independently being optionally substituted with one or more substituents selected from the group consisting of hydroxy, halogen, nitro and cyano; said cycloalkyl, heterocycloalkyl, aryl and heteroaryl each independently being optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, cyano, C 1-4 alkyl and C 1-4 alkoxy; and said heterocycloalkyl and heteroaryl each independently comprising at least one atom of N or O.